Interest in Haarlem Oil in the treatment cases of chronic bronchitis

JUSTIFICATION OF THE THERAPEUTIC TRIAL :

The cases of chronic bronchitis was frequently observed in paediatrics.

The significance of mucus modifiers in the treatment is actual, as witnessed in numerous publications and congresses that have treated it, among those that cited the latest symposiums: mucus and respiratory illnesses Paris, October 1988 and Bordeaux, May 1989.

The relevant cases of chronic bronchitis have come about due to various causes

Recurring infections in the E.N.T. sphere :

• Trouble in swallowing found a frequent breathing pathology.
• Bronchial Dsypnoea
• Abnormality of the vibratile cilia
  

It has to be added:

• The local bronchial tracheal lesions (eg. stenose tracheal post-intubation)
• The secondary bronchopneumonia dysplasies at long-assisted ventilation
• Mucoviscidosis
• Viral bronchioles in new-borns, etc...
  

Most of these etilogies are worsened by the eventual existence of an allergic ground or by a bronchial hypersensitivity originating from exogenous (passive tobacco, for example).

Page1

Clinical tables carried out at the time during chronic bronchitis, are dominated by:

The inflammation of chronic bronchial tracheal.

• With the huge mucus secretion, a cumbersome factor and persistent cough.

The inflammation favours the appearance of frequent episodes of viral or bacterial infection, modifying the characters of bronchial secretion that become purulent.

The aetiological diagnosis reached by chronic bronchitis and the evaluation of the respiratory function requires sometimes complimentary extensive examinations (bacterial and viral radiology, immunology, endoscopic examinations, functional lung tests, etc....)

Page 2

THE TREATMENTS

The treatments of chronic bronchitis syndromes consists of avoiding an aggravated evolution and is sometimes torpid from pathological bronchopneumonia against the definite internal injuries, particularly in the dilatation type of the bronchial tubes, in which the seriousness is known for the prognosis pulmonary function and vital in long terms.

The treatments call for aid

• From drainage physiotherapy
• From antibiotic cures at the time of secondary infection
• At modifications of the secretion of bronchial mucus
• At sulphuric therapeutic administered under different forms, which includes, thermal cures
  

If the interest of these treatments is undeniable, the disadvantages could  be underlined

• Allergic risks connected to antibiotics
• Cost of treatments (physiotherapy, antibiotics, thermal cures, immunotherapy)
• Relative inefficiency of therapeutic sulphur in the normal prescribed form.

Page 3

CLINICAL DOCUMENTATION

In the choice of treatment in the curative and prevention of chronic bronchitis, the interest is to benefit, sometimes though therapeutic ways

• Effective
• Non-poisonous
• Practical way of administrating
• The daily cost is not expensive
• All the elements that drives us to use and appreciate the antiseptic clinical effectiveness and mucus modificator of Haarlem Oil in children that suffer from various aetiological chronic bronchitis.

Page 4

HAARLEM OIL

Used in France since 1924.

Monograph from Vidal, viewed by the Alexandre commission (star monograph 1981)

The matter of sulphured terpens, in which the properties are that of the components, oxides of organic sulphur, terpene essence from turpentine.

Strong antiseptic action linked to the properties of turpentine essence.

Modified actions clarified from the numerous secretions, especially bronchial linked with sulphur.

The diffusion of Haarlem Oil is large in the organism, as it is experimentally shown by pharmacological studies. Its benefits are aimed at the digestive absorption, biliary elimination, tissue distribution, the constant plasma and the excretion of S35 in rats, after a unique oral dose of Haarlem Oil (therapeutic dose of 10mg/kg).

The study of Professor Jacquot (1984) shows an important tissue distribution and precociously, 15 minutes and on hour at the level of the bronchial-pulmonary tissues. The anti-inflammatory action is experimental, reported in a study by Professor Jacquot (1986), which notes a signifcative elevated action of SOD, probably by elevation of the thiols in the plasma. The absence of toxicity in Haarlem Oil relieves the three orders of established facts.

No case of intoxication has been reported by this medicine, since it has been on the market since 1924.

The study of toxicology, determines the lethal dose of 50 (EVIC CEBA 1988) from 2500mg/kg, is consequently infinitely higher than the recommended therapeutic dose, by the laboratory: 10mg/kg.

The risk of accidental intoxication is made non-existant and mainly in children.

One method of packaging is in a bottle of 10ml.

In the form of capsules, in a box of 32 capsules, 6.4g.

Due to the strong taste of the product, this speciality in the droplet form is highly sweetened for its administration. Children, on the other hand, chew a tablet and spit it out immediately.

Page 5

METHODOLOGY OF CLINICAL STUDIES

POSOLOGY:

HAARLEM OIL is prescribed :

• At a dose of 10mg per kilo and an initial cure of 10 days
• Eventually to be repeated 8 to 10 days per month, if required
  

Mode of administration :

Under the form of of drops mixed with sweet food.

Choice of patients :

25 children underwent a treatment of Haarlem Oil, after information provided and consentment of the parents.

Age of the children :

Between 5 months and 8 years.

All the patients had clinical symptoms of various etiological chronic bronchitis reported in the individual files and synthesised in the attached table.

Haarlem Oil was prescribed, excluding any other mucus-modifying treatments.

REMARKS :

It is noted that in only 2 patients, the assessments permitted relief from a very positive allergic ground.

Page 6

CINICAL FILE Nº2

1. Name : Aude B.
2. Date of Birth : 20.09.1984
3. Gestational Age : 38 weeks
4. Weight at Birth : 3 350 g
5. Neonatal Pathology : None
   

Evolution

From the age of 12 months: Rhinopharyngeal infections and repeated otitis, treated by repeated antibiotics and local disinfectants.

• Evolution towards a chronic bronchitis syndrome with subsequent infectious episodes
• At two and a half years old, adenoidectoderm without effect
• The allergic assessment is negative; test of sweat negative
• February 1988: Age: three years and six months. The child was tired by the multiple episodes of infectious bronchitis with permanent hypersecretion. The lung x-ray confirmed the syndrome of diffused bronchitis. Start of the treatment of Haarlem Oil 10 mg/kg, 10 days per month. The effect is remarkable with the disappearance of bronchial hypersecretion and cough, in less than one week. The effect was observed, since the first cure, and maintained by one consolidated cure, using the same posology, one month later.
• March 1990 : Age: five years and six months. Normal growth. The sensitivity of the child to frequent infectious bronchial hypersecretion, especially in the period of Autumn-Winter, has made to resume the treatment of Haarlem Oil, always at the same posology of 10 mg/kg with an excellent effect, avoiding a repetition of antibiotic cures.
  

Conclusion

The syndrome of secondary chronic bronchitis to E.N.T. recurring infections. Remarkable effect and residuals from Haarlem Oil.

Page 7

CLINICAL FILE Nº3

1. Name : Pamela B.
2. Date of Birth : 03.08.1984.
3. Gestational Age : 33 weeks
4. Weight at Birth : 1940 g
5. Neonatal Pathology : Birth by cesarean for hemorragic placenta / Infection of the hyalin membranes
   

Assisted ventilation during eight days: Favourable evolution and out of care at J 34

Evolution

Persistence of a hoarse voice with laryngeal dyspnea.

E.N.T. Infections (rhinopharyngitis and otitis) at consequent repetitions of permanent bronchial congestion

• At 10 months, the laryngoscopy confirmed the existence of a tracheal stenosis under-glotal, consequences of intubation.
• Adenoidectoderm
  

Following treatment : Pulmonary physiotherapy

Immunotherapy

Disfectants and local fluids.

• Between one and two and a half years old, persistence of multiple bronchial infection, requiring one occasion of hospitalisation for lung infected bacteria (HAEMOPHILUS).
• At two years and nine months: New bronchoscopy : persistence of tracheal roll and the existence of numerous intra-bronchial mucomucus-purulent secretions.
• At three years and eight months : Clear voice, good growth. Nevertheless, a persistent E.N.T. infection (mucus otitis and a reappearance of adenoide hypertrophy) still accompanied by a major bronchial congestion. The lung x-ray confirmed that the bronchitis had diffused with peripheral emphysema.
• At three years and ten months (April 1988) : Initial treatment of Haarlem Oil, 10mg/kg, 10 days per month. The effects were immediately efficient with a disappearance of the cough and the bronchial congestion, within four to five days. The monthly treatments were at that time followed at 10 days per month and were pursued thereafter, during six months. A systematic way as treatments were discontinued and repeated only at the reappearance of a bronchial infection, which were less frequent.
• At five years and nine months (May 1990) : Normal growth, normal lung functioning, normal lung x-ray, no infection nor bronchial-pulmonary pathology since one year.
  

Conclusion

Recurring secondary bronchial infections, bronchial-pulmonary at tracheal stenose, consequence of intubation. Remarkable effect of Haarlem Oil.

Page 8

CLINICAL FILE Nº4

1. Name : Alexandre M.
2. Date of Birth : 30.12.1984.
3. Gestational Age : 41 weeks
4. Weight at Birth : 3 380 g
5. Neonatal Pathology : None
   

Evolution

Bronchial virus at two months, otitis purulent at five months. Recurring otitis (transtympanic drainage at 10 months), with rhinopharyngitis and bronchial congestion.

• Adenoidectoderm at ten months
• Between ten months and two and half years old, multiple otitis infections and bronchitis justifying the antibiotic treatments and the repeated symptoms with physiotherapy drainage. The allergic assessment is negative, test of sweat negative, lung x-ray diffused bronchial syndromes without thoracic distension.
• September 1987 (two years and nine months), weight-16 kg. Unsuccessful treatment of a new bronchial episode with antibiotics (CEPHOPEROS), followed by an initial treatment of Haarlem Oil, 10mg/kg, during ten days. The effectiveness was excellent with the disappearance of clinical signs and lung congestion within four days. Reinforcement treatment systematically practised one month after the initial treatment, with the same posology.
• February 1988 (three years and two months) : Very good improvement. Had not any infection since the second cure of Haarlem Oil
  

The child has not been treated since this last consultation.

Conclusion

Chronic bronchitis a post-infection of E.N.T. Remarkable effect from Haarlem Oil since the first treatment.

Page 9

CLINICAL FILE Nº5

1. Name : Thibaut B.
2. Date of Birth : 25.10.1985.
3. Gestational Age : 39 weeks
4. Weight at Birth : 3 250 g
5. Neonatal Pathology : None
   

Evolution

At the age of 16 months, multiple rhinopharyngeal infections with mucus otitis and bronchial syndromes, resulting in persistent cough and noted by lung x-ray, with also bronchial congestion and thoracic distension.

• At two years, the allergic assessment is negative, test of sweat negative
• Growth and weight have not changed
• January 1988 (two years and three months) : Treatment of a new bronchial infection, initial treatment of Haarlem Oil, 10mg/kg. Immediate effectiveness in less than one week, but recurrence of cough and bronchial-pulmonary congestion fifteen days after stopping the treatment. Decision is made to continue Haarlem Oil for a monthly cure of 10 days per month, at the same posology.
• May 1988 : After four monthly treatments of Haarlem Oil, total disappearance of the major lung signs, congestion and cough. Weight gain, over 1kg in four months.
• April 1990 : Four and a half years old. The child was regularly observed. Regular growth for age. Perfect maintenance of lung function, in which the unusual episodes and occasional infection, observed since two years, justified the simple and effective treatment of Haarlem Oil and always at the same posology.
  

Conclusion

Secondary chronic bronchitis to multiple E.N.T. infections. Remarkable effect from Haarlem Oil with a positive indirect effect on growth.

Page10

CLINICAL FILE Nº7

1. Name : Charles Henry B.
2. Date of Birth : 29.03.1985
3. Gestational Age : 40 weeks
4. Weight at Birth : 2 590 g
5. Neonatal Pathology : Delay in intra-uterine growth
   

Evolution

From the age of three months, multiple rhinopharyngeal infections and mucus otitis developing into deafness of 25 DB, brought into evidence at three years.

Cough and bronchial congestion almost permanent. Multiple antibiotic treatments.

Allergic assessment is negative, test of sweat negative

Modest growth.

• April 1988 (three years) : Treatment of a new E.N.T. infection and bronchitis by an initial treatment of Haarlem Oil, 10mg/kg per day, during 10 days. Excellent effectiveness with the disappearance of clinical signs within four to five days, without relapse. Second systematic treatment one month after the initial treatment, with the same posology.
• March 1990 (five years) : The child was occasionally observed. Regular growth for age. Disappearance of the pathological E.N.T. and initial bronchitis. The appearance of occasional infections has brought about the re-use of Haarlem Oil, with the same effect as the initial treatment, avoiding resorting to antibiotics.
  

Conclusion

Recurring E.N.T. infections with deafness from post-otitis and chronic tracheal bronchitis. Major effectiveness and support from Haarlem Oil, from the initial treatment, with the influence on the revival of normal growth.

Page11

The study continues for more than 25 pages, that is held at your disposition, by simply inquiring at info@huile-de-harlem.com

COMMENTARIES

Our results, reported by clinical studies of 25 children, confirms the interest of the use of Haarlem Oil, in the treatments of chronic bronchial-pulmonary.

Recent publications (4,5) clearly show that the effectiveness of what was called "mucus-ciliary escalator" depends not only on the integrity of the epithelia cells, the co-ordination and movement of the ciliaries, but also the mucus rhinonogy characters, in which the threads and the viscoelasticity are altered and reduced in the cases of recurring bronchial-pulmonary infections.

Thus, the justification of the use of Haarlem Oil is as follows :

• The knowledge and its mucus modifying properties and pulmonary antiseptics known since a very long time.
• The absence of toxicity.
• Recent experiments done on animals have authorised and given human beings a bioavailibility and an identical action, with an important tissue fixation of sulphur on the level of bronchial-pulmonary.
• Our studies have been based on simple observations of clinical signs and on evolution.
  

It is difficult, and also the opinion of J. Battin (1), to have a large scale of controlled tests appreciating placebo and the effectiveness of mucus modificator, for the reason of diverse etiologies competing with chronic bronchial-pulmonary pathologies and the fact of complex complementary explorations. For these reasons, we have chosen the clinical appreciations and evolution, compared to other products, currently proposed in the treatment of these symptoms. In 68 % of the cases in our series, we observed since the first treatment of Haarlem Oil, the clarification and the disappearance of bronchial hyper-secretion, in less than one week. This confirms the positive rheological action of the antiseptic action of Haarlem Oil. These actions are continued with remanence after several weeks, in the majority of the cases. In 70 % of children, for which the renewing of the treatment of Haarlem Oil was proposed monthly, effectiveness followed favourably, bringing a total recovery of chronic bronchial-pulmonary, in less than four months. We can measure the savings also realised by the multiple treatments previously used (particularly the repeated antibiotic treatments). In the other cases, 60 % of which the monthly cures were continued either systematically or by request, the antiseptic action and clarification of trachael-bronchitis secretion were shown. Haarlem Oil obtained the disappearance of all congestional symptoms during the long periods and has also significally reduced the episodes of secondary infection, uniquely observed in children, in which the attack of chronic bronchial-pulmonary was considered as definitive.

The deleterious action on the bronchial mucus of free radicals of oxygen, is actually well known. They are incriminated in the pathology of the bronchial-pulmonary dysphasia (6). They are directly incriminated in the destruction of the local cellular structures and indirectly in the flow of the local inflammatory cells : macrophagics and polynuclears. All these factors contribute to the serious transudation of bronchial-alveolar.

The liberation of leukotrienes by the macrophages (3) favourise, by their bronchial-constructural action, the retention in the air passage. The role of toxic metabolizes of oxygen arising from the respiratory after-effects is more important than the antioxidant system of new borns, who are immature.

Therefore, the study of C. Jacquot (2), appears that it is essential. It has demonstrated, in animals, the antioxidant activity of Haarlem Oil. The activity of the super-oxidised dismutase enzyme, principal antioxidant enzyme of the organism, is significantly higher in the cases treated by Haarlem Oil, than in the witness groups. This increase reported an elevation of thiol groups in the plasma.

Page12

CONCLUSION

Used in 25 children that were infected with chronic bronchial-pneupathy of diverse etiologies, Haarlem Oil has shown a good effect in 68 % of the cases, since the first treatment and in 70 % of the cases, where the treatment was renewed monthly, the reduction and disappearance of clinical symptoms of bronchial hypersecretion.

This action was clearly superior to the mucus-modifying medication, comparably prescribed habitually.

It is desirable that the studies are continued particularly at the pharmacological level, next to the antiseptic actions and classic mucus-modificators known, of Haarlem Oil. Its antioxidant activity was recently brought into evidence, by the elevation of the activity of the super-oxidised dismutase, essential appearance in the prevention of pulmonary bronchial-dysplasia.